Ex­clu­sive: Backed with $350M, se­cre­tive start­up Met­sera jumps in­to the obe­si­ty race

Fund­ed with $350 mil­lion from top-tier VCs and led by a vet­er­an phar­ma CEO, a new obe­si­ty start­up called Met­sera has been qui­et­ly build­ing plans to get mul­ti­ple drugs in­to the clin­ic over the next two years, End­points News has ex­clu­sive­ly learned.

Met­sera’s CEO is Clive Mean­well, the for­mer chief ex­ec­u­tive of The Med­i­cines Com­pa­ny. The com­pa­ny was in­cor­po­rat­ed in 2022 by Pop­u­la­tion Health Part­ners, an in­vest­ment firm start­ed in 2020 by Mean­well and for­mer Pfiz­er CEO Ian Read.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER